New Weight Loss Pill Shows Promise in Reducing Kilos After Vaccinations
Eli Lilly (NYSE: LLY) and Novartis (NYSE: NVS) are racing to commercialize a $10/month oral follow-up pill for weight-loss patients post-semaglutide injections, targeting a $50B+ market by 2030. The pill—expected ... Read More